ArticleNeuropsychiatric disease and treatment2022

Serum NOX1 and Raftlin as New Potential Biomarkers of Interest in Schizophrenia: A Preliminary Study.

Onur Hurşitoğlu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.